Related Experiment Video
Updated: Aug 11, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Drug-induced liver injury: summary of a single topic clinical research conference
Paul B Watkins1, Leonard B Seeff
1University of North Carolina, Chapel Hill, NC, USA. pbwatkins@med.unc.edu
Abstract:
Idiosyncratic drug induced liver injury (DILI) remains poorly understood. It is assumed that the affected individuals possess a rare combination of genetic and non genetic factors that, if identified, would greatly improve understanding of the underlying mechanisms. This single topic conference brought together basic scientists, translational investigators, and clinicians with an interest in DILI. The goal was to define high priority areas of investigation that will soon be made possible by The Drug-Induced Liver Injury Network (DILIN). Since 2004 DILIN has been collecting clinical data, genomic DNA and some tissues from patients who have experienced bone fide DILI. The presentations spanned many different areas of DILI, and included novel data concerning mechanisms of hepatotoxicity, new "omics" approaches, and the challenges of improving causation assessment.
Insights
Idiosyncratic drug-induced liver injury (DILI) is poorly understood, likely due to rare genetic and non-genetic factors. The Drug-Induced Liver Injury Network (DILIN) aims to identify these factors and improve understanding of DILI mechanisms.
Area of Science:
- Hepatology
- Pharmacogenomics
- Translational Medicine
Background:
- Idiosyncratic drug-induced liver injury (DILI) presents a significant challenge in clinical practice due to its unpredictable nature.
- Understanding the underlying mechanisms of DILI is crucial for improving patient outcomes and drug safety.
Observation:
- A conference convened basic scientists, translational researchers, and clinicians focused on DILI.
- The Drug-Induced Liver Injury Network (DILIN), established in 2004, collects extensive clinical and biological data from DILI patients.
Findings:
- Presentations covered novel hepatotoxicity mechanisms, advanced 'omics' methodologies, and challenges in assessing DILI causality.
- DILIN's data resources are poised to enable high-priority investigations into DILI's complex etiology.
Implications:
- Identifying genetic and non-genetic factors contributing to DILI can significantly advance mechanistic understanding.
- Enhanced knowledge of DILI pathogenesis will facilitate the development of predictive biomarkers and improved diagnostic strategies.
Related Concept Videos
Drug Toxicity: Overview
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug Toxicity: Risk factors
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology

